title: The status of Tsukuba BNCT trial: BPA-based boron neutron capture therapy combined with X-ray irradiation.
abstract: The phase II trial has been prepared to assess the effectiveness of BPA (250 mg/kg)-based NCT combined with X-ray irradiation and temozolomide (75 mg/m(2)) for the treatment of newly diagnosed GBM. BPA uptake is determined by (18)F-BPA-PET and/or (11)C-MET-PET, and a tumor with the lesion to normal ratio of 2 or more is indicated for BNCT. The maximum normal brain point dose prescribed was limited to 13.0 Gy or less. Primary end point is overall survival.
authors.affiliation: Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai, Tsukuba, Japan. tetsu_tsukuba@yahoo.co.jp
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: K
authors.initials: K
authors.lastname: Nakai
authors.forename: T
authors.initials: T
authors.lastname: Nariai
authors.forename: H
authors.initials: H
authors.lastname: Kumada
authors.forename: T
authors.initials: T
authors.lastname: Okumura
authors.forename: M
authors.initials: M
authors.lastname: Mizumoto
authors.forename: K
authors.initials: K
authors.lastname: Tsuboi
authors.forename: A
authors.initials: A
authors.lastname: Zaboronok
authors.forename: E
authors.initials: E
authors.lastname: Ishikawa
authors.forename: H
authors.initials: H
authors.lastname: Aiyama
authors.forename: K
authors.initials: K
authors.lastname: Endo
authors.forename: T
authors.initials: T
authors.lastname: Takada
authors.forename: F
authors.initials: F
authors.lastname: Yoshida
authors.forename: Y
authors.initials: Y
authors.lastname: Shibata
authors.forename: A
authors.initials: A
authors.lastname: Matsumura
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D016754:Boron Neutron Capture Therapy; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D049268:Positron-Emission Tomography; D000077204:Temozolomide
chemical_list: D000970:Antineoplastic Agents; D003606:Dacarbazine; D000077204:Temozolomide